Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research report issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on ITCI. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Piper Sandler restated a “neutral” rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, Canaccord Genuity Group cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their price objective for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Ten analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies has an average rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Trading Down 0.0 %

Shares of NASDAQ ITCI opened at $131.24 on Wednesday. The stock has a market cap of $13.95 billion, a price-to-earnings ratio of -150.85 and a beta of 0.69. Intra-Cellular Therapies has a 1-year low of $63.30 and a 1-year high of $131.37. The stock’s 50-day moving average is $121.11 and its 200 day moving average is $94.48.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, analysts forecast that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Accredited Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies in the fourth quarter worth $28,000. True Wealth Design LLC purchased a new position in shares of Intra-Cellular Therapies in the third quarter worth $32,000. GAMMA Investing LLC raised its stake in shares of Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Intra-Cellular Therapies in the fourth quarter worth $96,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Intra-Cellular Therapies in the third quarter worth $97,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.